CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 36 enrolled
Drug / intervention
Sodium hyaluronate 3% +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04702802
NCT04702802N/ACompleted
CompareCT.gov

Clinical Study to Evaluate the Safety of the Viscoelastic Substance PRO-149 When Used as a Device During Phacoemulsification and Intraocular Lens Implantation in Patients With Age-related Cataract, Compared to Healon® EndoCoat.

Laboratorios Sophia S.A de C.V.·interventional·Posted Jan 11, 2021·Updated Dec 16, 2025

In Brief

A clinical study evaluating Sodium hyaluronate 3% for Age-related Cataract and Phacoemulsification. Completed, enrolled 36 participants across 1 site.

Detailed Summary

Pilot, controlled, parallel group, open, randomized clinical trial to evaluate the safety of the viscoelastic substance PRO-149 (sodium hyaluronate 3%) after trans-surgical administration as a device in performing phacoemulsification and intraocular lens implantation in 36 patients with age-related cataract, compared to Healon® EndoCoat (sodium hyaluronate 3%).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-related Cataract, Phacoemulsification
CountriesMexico
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJan 11, 2021
Enrollment StartSep 7, 2021
Primary CompletionOct 29, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.5 years ago

Interventions

Sodium hyaluronate 3%device

During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.

Sodium hyaluronate 3%device

During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.